Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 12:59 am
Share
Bukwang Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 0.00023 million compared to KRW 0.00001 million a year ago. Net loss was KRW 421.4 million compared to KRW 266.51 million a year ago. Basic loss per share from continuing operations was KRW 6 compared to KRW 4 a year ago. Diluted loss per share from continuing operations was KRW 5 compared to KRW 4 a year ago. Basic loss per share was KRW 6 compared to KRW 4 a year ago.
For the six months, negative sales was KRW 0.00092 million compared to sales of KRW 0.00001 million a year ago. Net loss was KRW 2,541.82 million compared to KRW 3,482.98 million a year ago. Basic loss per share from continuing operations was KRW 37 compared to KRW 51 a year ago. Diluted loss per share from continuing operations was KRW 37 compared to KRW 51 a year ago. Basic loss per share was KRW 37 compared to KRW 51 a year ago.
Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.